Glucocorticoides inhalados y sibilancias posbronquiolitis
- M. Callén Blecua
- P. Aizpurua Galdeano
- I. Ozcoidi Erro
- L. Mancisidor Aguinagalde
- C. Guedea Adiego
- E. Busselo Ortega
- I. Ibarrondo Uriarte
Year of publication: 2000
Volume: 52
Issue: 4
Pages: 351-355
Type: Article
Sustainable development goals
Abstract
To determine whether inhaled corticosteroid therapy given for 3 months after mild bronchiolitis decreases the incidence and/or severity of wheezing in the following 12 months. Design Multicentric, single-blind, controlled, randomised intervention study. Setting Primary Health Care Centers in Lezo, Beraun, Andoain and Irún (Gipuzkoa, Spain). Patients Infants less than 12 months old (n = 94) diagnosed with mild bronchiolitis. Intervention We established two groups of patients: group 1 (n = 47) was treated with inhaled beclomethasone (250 µg/12 hours) using a valved holding chamber (Babyhaler®); the treatment started eight days after diagnosis of bronchiolitis and lasted 3 months. Group 2 (n = 47) received no treatment. We compared the number of wheezing episodes and their severity during the intervention period (3 months) and the follow-up period (12 months) with the Student's t-test and the Chi-squared test. Results We studied 89 infants (group 1, n = 42; group 2, n = 47), 67% of whom wheezed during the study period (15 months). There were no significant differences between the treatment and the control group in the study periods. Conclusions Inhaled beclomethasone given for 3 months does not significantly modify the occurrence of wheezing episodes during the treatment period or during the following 12 months.